Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 495 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox Clear all
Completed Phase 2 Interventional

Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

NCT00651729
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
21 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 20, 2026, 4:29 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404
View directory record Official record
Conditions
Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 4:29 AM EDT
Terminated Phase 3 Interventional

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01818076
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 20, 2026, 4:29 AM EDT
Not listed Phase 3 Interventional

Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain

NCT00211718
View directory record Official record
Conditions
Arthritis, Shoulder Pain
Interventions
intra-articular botulinum toxin type a
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2005 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Botox and Vibration on Bone in Children With Cerebral Palsy

NCT01803464
View directory record Official record
Conditions
Cerebral Palsy, Muscle Spasticity
Interventions
Low-magnitude vibration, Botox
Device · Drug
Lead sponsor
University of Delaware
Other
Eligibility
2 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Newark, Delaware • Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma

NCT04523506
View directory record Official record
Conditions
Scleroderma
Interventions
Botulinum toxin(Botox)
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01940991
View directory record Official record
Conditions
Skin Aging
Interventions
Placebo, Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 4 Interventional

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

NCT00168480
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2008 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 1 Interventional

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

NCT05769478
View directory record Official record
Conditions
Botulism, Iatrogenic Botulism
Interventions
Amifampridine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 20, 2026, 4:29 AM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Upper Limb Spasticity

NCT02074150
View directory record Official record
Conditions
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Not applicable Interventional

EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction

NCT01323829
View directory record Official record
Conditions
High Tone Pelvic Floor Dysfunction
Interventions
EMG Guidance of Injection
Other
Lead sponsor
Pelvic and Sexual Health Institute
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)

NCT01502956
View directory record Official record
Conditions
Urinary Incontinence, Urge
Interventions
InterStim® device, Botox® injection
Device · Drug
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • La Jolla, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 20, 2026, 4:29 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

NCT04099667
View directory record Official record
Conditions
Spasticity
Interventions
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin in the Treatment of Raynaud's

NCT01233999
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 4 Interventional Results available

Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

NCT01486264
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Xeomin®
Biological
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Fountain Valley, California • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function

NCT00076687
View directory record Official record
Conditions
Stroke, Muscle Spasticity, Motor Neuron Disease
Interventions
botulinum toxin Type A, saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 3 Interventional Results available

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

NCT05134649
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encino, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 20, 2026, 4:29 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

NCT05606757
View directory record Official record
Conditions
Ventral Hernia, Abdominal Hernia
Interventions
BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B, BOTOX Dose C
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Mineola, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulinum Toxin for Pelvic Pain in Women With Endometriosis

NCT01553201
View directory record Official record
Conditions
Endometriosis, Chronic Pelvic Pain, Pelvic Muscle Spasm, Quality of Life
Interventions
Botulinum toxin (BoNT), Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 20, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

NCT06293300
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
BoNT A
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 20, 2026, 4:29 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines

NCT07871513
View directory record Official record
Conditions
Upper Facial Lines, Glabellar Lines
Interventions
TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Glendale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 4:29 AM EDT
Not yet recruiting Phase 4 Interventional

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 20, 2026, 4:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 20, 2026, 4:29 AM EDT